Design Therapeutics annual free cash flow
2020
2021
2022
2023
2024
2025
Design Therapeutics Free Cash Flow (FCF) History (DSGN)
Design Therapeutics reported −$54.6M in free cash flow for fiscal 2025, a decrease of $11.1M from the previous fiscal year.
View full Design Therapeutics company overviewDesign Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$54.6M | −$11.1M | — | — |
| 2024 | 2024-12-31 | −$43.4M | $15.4M | — | — |
| 2023 | 2023-12-31 | −$58.8M | −$6.6M | — | — |
| 2022 | 2022-12-31 | −$52.2M | −$21.3M | — | — |
| 2021 | 2021-12-31 | −$30.9M | −$22.2M | — | — |
| 2020 | 2020-12-31 | −$8.7M | — | — | −3869.47% |
Design Therapeutics quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$15.5M | −$1.0M | — | — |
| Q1 2026 | 2026-03-31 | −$16.4M | $430,000 | — | — |
| Q4 2025 | 2025-12-31 | −$12.0M | −$2.1M | — | — |
| Q3 2025 | 2025-09-30 | −$11.2M | −$1.6M | — | — |
| Q2 2025 | 2025-06-30 | −$14.5M | −$3.1M | — | — |
| Q1 2025 | 2025-03-31 | −$16.9M | −$4.2M | — | — |
| Q4 2024 | 2024-12-31 | −$9.9M | $3.0M | — | — |
| Q3 2024 | 2024-09-30 | −$9.6M | $5.0M | — | — |
| Q2 2024 | 2024-06-30 | −$11.4M | $2.5M | — | — |
| Q1 2024 | 2024-03-31 | −$12.6M | $4.9M | — | — |
| Q4 2023 | 2023-12-31 | −$12.8M | $2.6M | — | — |
| Q3 2023 | 2023-09-30 | −$14.6M | −$378,000 | — | — |
| Q2 2023 | 2023-06-30 | −$13.9M | −$3.1M | — | — |
| Q1 2023 | 2023-03-31 | −$17.5M | −$5.6M | — | — |
| Q4 2022 | 2022-12-31 | −$15.4M | −$5.8M | — | — |
| Q3 2022 | 2022-09-30 | −$14.2M | −$5.1M | — | — |
| Q2 2022 | 2022-06-30 | −$10.7M | −$2.3M | — | — |
| Q1 2022 | 2022-03-31 | −$11.9M | −$8.2M | — | — |
| Q4 2021 | 2021-12-31 | −$9.6M | — | — | — |
| Q3 2021 | 2021-09-30 | −$9.1M | — | — | — |
| Q2 2021 | 2021-06-30 | −$8.5M | — | — | — |
| Q1 2021 | 2021-03-31 | −$3.7M | — | — | — |
Design Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$8.7M to −$54.6M, a net decrease of $45.8M. Design Therapeutics's latest reported quarter, Q2 2026, generated −$15.5M in free cash flow, a decrease of $1.0M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Design Therapeutics filings at SEC.gov ↗